<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05075421</url>
  </required_header>
  <id_info>
    <org_study_id>Gulhane2021-69</org_study_id>
    <nct_id>NCT05075421</nct_id>
  </id_info>
  <brief_title>Prognostic Values of Inflammation-based Indices in Gastric Cancer</brief_title>
  <official_title>Comparison of the Prognostic Values of Preoperative Inflammation-based Indices in Patients Undergoing Resection of Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gulhane Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gulhane Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the prognostic values of preoperative inflammation-based indices&#xD;
      in patients undergoing potentially curative resection of gastric cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gastric cancer is one of the most common and deadly cancers worldwide. Based on GLOBOCAN 2018&#xD;
      data, it is the fifth most common malignancy and the third leading cause of cancer deaths,&#xD;
      with an estimated 783,000 deaths in 2018. Despite advances in diagnosis and management&#xD;
      strategies, outcomes for patients diagnosed with gastric cancer still remain poor and the&#xD;
      five-year survival is approximately %20. In addition, there is marked heterogeneity in the&#xD;
      duration of survival among patients. Hence, there are increasing research efforts towards the&#xD;
      identification of possible predictive clinical, pathological, or biologic factors to&#xD;
      determine more accurate patient stratification, which will improve clinical decision-making&#xD;
      and possibly contribute to more rational study design and analysis. Systemic inflammation is&#xD;
      known to play a crucial role in the pathogenesis, development, and progression of cancer.&#xD;
      Preoperative inflammation-based indices, such as the Glasgow prognostic score (GPS), modified&#xD;
      Glasgow prognostic score (mGPS), neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio&#xD;
      (PLR), prognostic index (PI), prognostic nutritional index (PNI), CRP/albumin ratio, systemic&#xD;
      inflammation score (SIS), modified systemic inflammation score (mSIS), have been found to&#xD;
      have potential prognostic values in various cancer. Previous studies have suggested that&#xD;
      several of these scoring systems may have a role in predicting survival in patients with&#xD;
      upper gastrointestinal cancer. These scores are all derived from blood tests that are already&#xD;
      routinely performed in clinical practice and thus have the potential to offer valuable&#xD;
      additional information that may help to guide patient management. This study aims to evaluate&#xD;
      the prognostic values of preoperative inflammation-based indices in patients undergoing&#xD;
      potentially curative resection of gastric cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>5-year survival rates</measure>
    <time_frame>5 years</time_frame>
    <description>The primary clinical outcome of interest is 5-year survival rates.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1 (high marker)</arm_group_label>
    <description>Patients with elevated serum markers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 (normal marker)</arm_group_label>
    <description>Patients with normal value of serum markers</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrectomy</intervention_name>
    <description>Any type of gastrectomy for gastric cancer</description>
    <arm_group_label>Group 1 (high marker)</arm_group_label>
    <arm_group_label>Group 2 (normal marker)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged â‰¥ 18 years who underwent a surgical procedure for gastric cancer are included&#xD;
        in this study&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over the age of 18 who underwent a surgical procedure for gastric cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients &lt; 18 years of age&#xD;
&#xD;
          -  Patients with no routine blood examination before surgery or incomplete medical&#xD;
             records&#xD;
&#xD;
          -  Patients followed up less than 3 months&#xD;
&#xD;
          -  Patients with additional malignancy&#xD;
&#xD;
          -  Patients having tumors that invading adjacent organs&#xD;
&#xD;
          -  Patients with adjacent or distant metastasis&#xD;
&#xD;
          -  Patients receiving neoadjuvant therapy (chemo- or radiotherapy)&#xD;
&#xD;
          -  Patients with previous malignancy history&#xD;
&#xD;
          -  Patients with a clinical evidence of infection&#xD;
&#xD;
          -  Patients with a history of preoperative use of anti-inflammatory drugs or&#xD;
             immunosuppressive treatment&#xD;
&#xD;
          -  Patients with a history of chronic inflammatory disease or autoimmune disease&#xD;
&#xD;
          -  Patients who underwent emergency surgical resection&#xD;
&#xD;
          -  Patients who have undergone R1/R2 resection or those with positive peripheral margins&#xD;
&#xD;
          -  Patients with missing data on follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suleyman U Celik</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gulhane Training and Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Suleyman U Celik, MD</last_name>
    <phone>+90 (312) 304 2000</phone>
    <phone_ext>5121</phone_ext>
    <email>s.utkucelik@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gulhane Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suleyman U Celik, MD</last_name>
      <phone>+90 (312) 304 2000</phone>
      <phone_ext>5121</phone_ext>
      <email>s.utkucelik@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Suleyman U Celik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Wen J, Bedford M, Begum R, Mitchell H, Hodson J, Whiting J, Griffiths E. The value of inflammation based prognostic scores in patients undergoing surgical resection for oesophageal and gastric carcinoma. J Surg Oncol. 2018 Jun;117(8):1697-1707. doi: 10.1002/jso.25057. Epub 2018 May 14.</citation>
    <PMID>29761518</PMID>
  </reference>
  <reference>
    <citation>Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006 Mar 13;94(5):637-41.</citation>
    <PMID>16479253</PMID>
  </reference>
  <reference>
    <citation>Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC. An elevated C-reactive protein concentration, prior to surgery, predicts poor cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. Br J Cancer. 2006 Jun 5;94(11):1568-71.</citation>
    <PMID>16685271</PMID>
  </reference>
  <reference>
    <citation>Crumley AB, Stuart RC, McKernan M, Going JJ, Shearer CJ, McMillan DC. Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system. J Gastrointest Surg. 2010 May;14(5):781-7. doi: 10.1007/s11605-010-1162-6. Epub 2010 Feb 11.</citation>
    <PMID>20148314</PMID>
  </reference>
  <reference>
    <citation>Dutta S, Crumley AB, Fullarton GM, Horgan PG, McMillan DC. Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg. 2012 Sep;204(3):294-9. doi: 10.1016/j.amjsurg.2011.10.015. Epub 2012 Mar 22.</citation>
    <PMID>22444831</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 2, 2021</study_first_submitted>
  <study_first_submitted_qc>October 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 2, 2021</last_update_submitted>
  <last_update_submitted_qc>October 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gulhane Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Suleyman Utku Celik</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Survival</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Systemic inflammatory response</keyword>
  <keyword>Markers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share IPD</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

